EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Progress on the development of Class A GPCR‐biased ligands

Paula Morales, Magdalena M Scharf iD, Marcel Bermudez iD, Attila Egyed, Rafael Franco iD, Olivia K Hansen, Nadine Jagerovic, Jan Jakubík iD, György M Keserű, Dóra Judit Kiss, Pawel Kozielewicz iD, Olav Larsen and 9 more

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.17301 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, 2025. Written by Paula Morales and 20 co-authors. Institution: Instituto de Química Médica, Consejo Superior de Investigaciones Científicas, Madrid, Spain. Major MEDLINE topics: Receptors, G-Protein-Coupled, Drug Discovery. Cited 22 times so far (Crossref); 231 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Office of Research, Development and Innovation, Ministerio de Ciencia e Innovación, Cancerfonden.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Class A G protein‐coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numerous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and therapeutic value. In this context, the elucidation of biased signalling has opened up new pharmacological avenues holding promise for safer therapeutics. Functionally selective ligands favour receptor conformations facilitating the recruitment of specific effectors and the modulation of the associated pathways. This review surveys the current drug discovery landscape of GPCR‐biased modulators with a focus on recent advances. Understanding the biological effects of this preferential coupling is at different stages depending on the Class A GPCR family. Therefore, with a focus on individual GPCR families, we present a compilation of the functionally selective modulators reported over the past few years. In doing so, we dissect their therapeutic relevance, molecular determinants and potential clinical applications. LINKED ARTICLES This article is part of a themed issue Complexity of GPCR Modulation and Signaling (ERNST). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.14/issuetoc

Subjects

MeSH terms (MEDLINE)

Receptors, G-Protein-CoupledDrug DiscoveryHumansLigandsAnimalsSignal TransductionDrug Development

Author keywords

G protein‐coupled receptorsGPCR modulatorsbiased signallingfunctionally selective ligands

Substances

Receptors, G-Protein-CoupledLigands

Authors and institutions

  • Instituto de Química Médica, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
  • Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Institute for Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany.
  • Medicinal Chemistry Research Group and National Drug Discovery and Development Laboratory, Research Centre for Natural Sciences, Budapest, Hungary.
  • Molecular Neurobiology Laboratory, Department of Biochemistry and Molecular Biology, Universitat de Barcelona, Barcelona, Spain.
  • CiberNed. Network Center for Neurodegenerative Diseases, National Spanish Health Institute Carlos III, Madrid, Spain.

ORCID profiles: Magdalena M Scharf, Marcel Bermudez, Rafael Franco, Jan Jakubík, Pawel Kozielewicz, Gemma Navarro, Mette M Rosenkilde, Holger Stark

Funding

  • National Office of Research, Development and Innovation
  • Ministerio de Ciencia e Innovación
  • Cancerfonden
  • NIH HHS
  • German Research Foundation
  • Swedish Society for Medical Research
  • Hungarian Academy of Sciences
  • Consellería de Cultura, Educación e Ordenación Universitaria of the Galician Government

Cite

APA

Morales, P., Scharf, M. M., Bermudez, M., Egyed, A., Franco, R., Hansen, O. K., Jagerovic, N., Jakubík, J., Keserű, G. M., Kiss, D. J., Kozielewicz, P., Larsen, O., Majellaro, M., Mallo-Abreu, A., Navarro, G., Prieto-Díaz, R., Rosenkilde, M. M., Sotelo, E., Stark, H., …, & Wingler, L. M. (2025). Progress on the development of Class A GPCR‐biased ligands. British Journal of Pharmacology. https://doi.org/10.1111/bph.17301

Vancouver

Morales P, Scharf MM, Bermudez M, Egyed A, Franco R, Hansen OK, et al. Progress on the development of Class A GPCR‐biased ligands. British Journal of Pharmacology. 2025. doi:10.1111/bph.17301

BibTeX
@article{Morales2025,
  author = {Morales, Paula and Scharf, Magdalena M and Bermudez, Marcel and Egyed, Attila and Franco, Rafael and Hansen, Olivia K and Jagerovic, Nadine and Jakubík, Jan and Keserű, György M and Kiss, Dóra Judit and Kozielewicz, Pawel and Larsen, Olav and Majellaro, Maria and Mallo-Abreu, Ana and Navarro, Gemma and Prieto-Díaz, Rubén and Rosenkilde, Mette M and Sotelo, Eddy and Stark, Holger and Werner, Tobias and Wingler, Laura M},
  title = {Progress on the development of Class A GPCR‐biased ligands},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.17301}
}
Start for free →